Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 161.089 Deferred Share Units as a compensation-related award tied to deferral of his cash retainer under the company’s Deferred Fee Plan for Directors. Following this grant, he holds a total of 6,411.959 Deferred Share Units. These units, including dividend equivalent rights, are to be settled in cash upon the end of his board service and mirror the value of one common share each at settlement.
Johnson & Johnson director Daniel E. Pinto received a grant of 134.241 Deferred Share Units on June 9, 2026, tied to a reference price of $232.79 per unit. After this award, he holds 2,320.824 Deferred Share Units.
The units were acquired by deferring his cash retainer under the company’s Amended and Restated Deferred Fee Plan for Directors. These Deferred Share Units are settled in cash when his board service ends and each unit reflects the fair market value of one share of common stock at settlement, including dividend equivalent rights credited over time.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson reported receiving 214.786 Deferred Share Units on June 9, 2026 as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These units represent deferred cash retainers and are to be settled in cash when her board service ends, bringing her total Deferred Share Units to 15,791.877, including amounts accrued as dividend equivalent rights.
Johnson & Johnson filed a Form 13F reporting institutional holdings. The Form 13F Information Table lists 16 entries with a total market value of $652,355,946. The report was signed by Marc Larkins on 05-13-2026 and names one other included manager: Johnson & Johnson Innovation - JJDC, Inc.
JOHNSON & JOHNSON EVP John C. Reed reported routine equity compensation activity involving restricted share units (RSUs) and tax withholding. On May 1, 2026, RSUs covering 25,255 shares of Common Stock vested and were exercised into shares.
To cover taxes due at vesting, 11,002 shares of Common Stock were withheld at a reference price of $229.85 per share. After these transactions, Reed directly owned 24,911 shares of Johnson & Johnson Common Stock. This reflects RSU vesting and related tax withholding, not an open-market purchase or sale.
Johnson & Johnson reported that Vanguard Capital Management beneficially owned 180,631,228 shares of Common Stock, representing 7.49% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 180,631,228 shares and sole voting power for 24,025,858 shares.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.
After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 975 Deferred Share Units (DSUs) as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These DSUs are to be settled in cash when his directorship ends, with each DSU equal to the fair market value of one Johnson & Johnson common share on the settlement date.
After this award, Woods holds a total of 6,215.094 DSUs, including dividend equivalent rights that accrue on DSUs in connection with the company’s quarterly dividend. The transaction reflects compensation in the form of deferred, cash-settled, share-linked units rather than an open-market stock purchase or sale.
Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.
Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.
Johnson & Johnson director Nadja West received a grant of 975 Deferred Share Units (DSUs) on April 23, 2026. These DSUs were acquired under the company’s Amended and Restated Deferred Fee Plan for Directors at a price of $0.00 per unit.
Following this award, West holds a total of 7,730.0491 DSUs. Each DSU will be settled in cash upon the end of her board service, with each unit representing the fair market value of one share of Johnson & Johnson common stock on the settlement date. The holding also includes dividend equivalent rights that accrue as the company pays its quarterly dividend.
Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.
According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.
Johnson & Johnson director Mark A. Weinberger received a grant of 975 Deferred Share Units (DSUs) on Common Stock, reported as a compensation-related acquisition at a price of $0.00 per unit. After this grant, he holds a total of 12,010.408 DSUs directly.
According to the plan terms, these DSUs are to be settled in cash when his service as a director ends, with each DSU valued at the fair market value of one share of Common Stock on the settlement date. The reported holdings also include dividend equivalent rights that accrue on DSUs in line with Johnson & Johnson’s quarterly dividend.